Literature DB >> 29624462

Minimal Residual Disease Testing After Induction Chemotherapy for Acute Myeloid Leukemia: Moving Beyond Prognostication?

Roland B Walter1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29624462     DOI： 10.1200/JCO.2018.78.3266

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

Review 1.  Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.

Authors:  Franklin Fuda; Weina Chen
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

2.  CombiFlow: combinatorial AML-specific plasma membrane expression profiles allow longitudinal tracking of clones.

Authors:  Roos Houtsma; Nisha K van der Meer; Kees Meijer; Linde M Morsink; Shanna M Hogeling; Carolien M Woolthuis; Emanuele Ammatuna; Marije T Nijk; Bauke de Boer; Gerwin Huls; André B Mulder; Jan Jacob Schuringa
Journal:  Blood Adv       Date:  2022-04-12

3.  Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia.

Authors:  Tali Azenkot; Brian A Jonas
Journal:  Cancers (Basel)       Date:  2022-07-26       Impact factor: 6.575
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.